Atezolizumab


Thông tin kê toa tóm tắt
Chỉ định/Công dụng
Listed in Dosage.
Liều dùng/Hướng dẫn sử dụng
Adult : IV Locally advanced urothelial carcinoma; Metastatic urothelial carcinoma 1.2 g once every 3 weeks via infusion over 60 minutes, until disease progression or unacceptable toxicity. Locally advanced non-small cell lung carcinoma; Metastatic non-small cell lung carcinoma For previously treated: 1.2 g once every 3 weeks via infusion over 60 minutes, until disease progression or unacceptable toxicity. As first-line treatment: 1.2 g on day 1 every 3 weeks via infusion over 60 minutes followed by bevacizumab, paclitaxel, and carboplatin for 4-6 cycles of chemotherapy, until disease progression or unacceptable toxicity occurs. All doses may be modified, interrupted, or discontinued (based on severity) if immune- or infusion-related reactions occur.
Dosage Details
Intravenous
Locally advanced urothelial carcinoma, Metastatic urothelial carcinoma
Adult: 1.2 g once every 3 weeks via infusion over 60 minutes, until disease progression or unacceptable toxicity. Dose modification, interruption, or discontinuation (based on severity) may be required if immune- or infusion-related reactions occur (refer to detailed product guideline).

Intravenous
Locally advanced non-small cell lung carcinoma, Metastatic non-small cell lung carcinoma
Adult: For previously treated: 1.2 g once every 3 weeks via infusion over 60 minutes, until disease progression or unacceptable toxicity. As first-line treatment: 1.2 g on day 1 every 3 weeks via infusion over 60 minutes followed by bevacizumab, paclitaxel, and carboplatin for 4-6 cycles of chemotherapy, until disease progression or unacceptable toxicity occurs. Dose modification, interruption, or discontinuation (based on severity) may be required if immune- or infusion-related reactions occur (refer to detailed product guideline).
Hướng dẫn pha thuốc
Withdraw 20 mL and dilute in 250 mL NaCl 0.9% solution to prepare a final concentration 4.4 mg/mL. Mix gently. Do not shake.
Thận trọng
Pregnancy and lactation.
Phản ứng phụ
Significant: Endocrine disorders (e.g. hyper/hypothyroidism, type 1 diabetes mellitus, adrenal insufficiency), hypophysitis, uveitis, iritis, other immune-mediated effects (e.g. meningoencephalitis, myasthenia gravis, Guillain-Barre syndrome), pancreatitis, myocarditis.
Blood and lymphatic system disorders: Thrombocytopenia, autoimmune hemolytic anaemia.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain, dysphagia.
General disorders and admin site conditions: Pyrexia, fatigue, asthenia, influenza-like illness.
Immune system disorders: Hypersensitivity.
Investigations: Increased AST and ALT.
Metabolism and nutrition disorders: Decreased appetite, hypokalaemia, hyponatremia.
Musculoskeletal and connective tissue disorders: Arthralgia, back pain, musculoskeletal pain, chills.
Respiratory, thoracic and mediastinal disorders: Cough, dyspnoea, hypoxia, nasal congestion, nasopharyngitis.
Skin and subcutaneous tissue disorders: Rash, pruritus.
Vascular disorders: Hypotension.
Potentially Fatal: Immune-related hepatitis, pneumonitis and interstitial lung disease, colitis or diarrhoea, severe infection (e.g. sepsis, herpes encephalitis), infusion-related reactions.
Thông tin tư vấn bệnh nhân
This drug may cause fatigue, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor PD-L1 expression status, LFT, thyroid function, serum glucose; signs/symptoms of colitis, diarrhoea, endocrinopathies, hepatitis, hypophysitis, infection, infusion reactions, pneumonitis, and ocular toxicity.
Tương tác
May enhance the adverse effect of belimumab.
Tác dụng
Description: Atezolizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody which binds to programmed death ligand 1 (PD-L1) and selectively prevents the interaction between PD-1 and B7.1 (also known as CD80) receptors found on T-cells and antigen presenting cells, releasing PD-L1/PD-1 mediated inhibition of immune response thereby enhancing the immune response to tumour cells.
Pharmacokinetics:
Distribution: Volume of distribution at steady state: 6.9 L.
Excretion: Elimination half-life: 27 days.
Bảo quản
Store between 2-8°C. Do not freeze. Protect from light.
This is a cytotoxic drug. Any unused portions should be disposed of in accordance with local requirements.
Phân loại MIMS
Phân loại ATC
L01XC32 - atezolizumab ; Belongs to the class of monoclonal antibodies, other antineoplastic agents. Used in the treatment of cancer.
Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Atezolizumab từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2020 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in